What We're Reading: Page 309
Industry reads hand-picked by our editors
Mar 30, 2017
Mar 29, 2017
-
The American Prospect
The hidden monopolies that raise drug prices
-
Fortune
Trump is slashing FDA rules. Why isn’t big pharma excited?
-
Bloomberg
A new kind of male birth control is coming
-
The Wall Street Journal
FDA nominee plans recusals from decisions on many drug firms
Mar 28, 2017
-
MIT Technology Review
Is this the anti-aging pill we’ve all been waiting for?
-
MarketWatch
Ex-CEO Michael Pearson sues Valeant over unpaid shares
-
The New Yorker
Silicon Valley's quest to live forever
Mar 27, 2017
-
Business Insider
Trump is tapping Chris Christie to tackle the opioid epidemic — here's a fix scientists hope he'll explore
-
PBS
Venezuela’s hospitals face crisis as meds run low
-
The San Diego Union-Tribune
Should some patients be allowed to take drugs not yet cleared by FDA?
-
The Hill
Sanders will 'absolutely' work with Trump to lower prescription drug costs
Mar 24, 2017
-
Crain's Chicago Business
Pharma gets roped into the Trumpcare maelstrom
-
The Wall Street Journal
Valeant CEO Joseph Papa was paid $62.7 million in 2016
-
San Francisco Business Times
Google life sciences spinoff soaks up huge space
-
TheStreet
CFO says Depomed to buy or be sold
-
Philly.com
How a theft in Northeast Philly led to a drug firm's conviction for a $180 million fraud
Mar 23, 2017
Mar 22, 2017
-
Business Insider
Something weird's going on with the doctors prescribing one of pharma's most controversial blockbuster drugs
-
Kaiser Health News
Trump’s promise to rein in drug prices could open floodgate to importation laws
-
The Advocate
Purdue Pharma seeks dismissal of Washington state city’s lawsuit
-
Boston Business Journal
As Cerulean Pharma winds down, executives get a parting gift: bonuses
-
The New York Times
‘Cure’ me? No, thanks
Previous
